Dr Peter Würtz is Scientific Director and co-founder of Nightingale Health Plc, the Finnish innovator of an internationally recognized biomarker platform widely used for biobanks and clinical trials.

Dr Würtz is principal investigator of the Nightingale initiative on NMR-based biomarker profiling of the entire UK Biobank of 500.000 plasma samples.

The Nightingale platform has been approved for clinical use and is available direct-to-consumers and via healthcare partners in Scandinavia. Dr Würtz’ research focuses on translation of results from population studies into preventative health solutions for individuals.